Form 4: QuidelOrtho COO McLellan Reports Equity Transactions

QuidelOrtho's Chief Operations Officer, Philip D. McLellan, reported the acquisition of new restricted stock units and stock options, alongside the vesting and tax-related disposition of previously granted equity.

Summary

• Philip D. McLellan, Chief Operations Officer of QuidelOrtho Corp (QDEL), reported several equity transactions.
• On January 30, 2026, McLellan acquired 36,152 Restricted Stock Units (RSUs) and 36,150 Non-Qualified Stock Options, both with a $0 acquisition price.
• The newly acquired RSUs will vest with 12,050 shares on January 30, 2027, and the remaining 24,102 shares in equal installments on January 30, 2028, and January 30, 2029.
• The newly acquired stock options will vest in equal installments on January 30, 2027, January 30, 2028, and January 30, 2029, with an exercise price of $27.17 and an expiration date of January 30, 2036.
• On January 31, 2026, McLellan acquired a total of 4,617 shares of common stock ($0 price) from the release of previously reported restricted stock units.
• Concurrently, McLellan disposed of a total of 1,627 shares of common stock at a price of $27.17 per share to satisfy tax withholding obligations related to the RSU releases.
• Following these transactions, McLellan beneficially owns 19,174 shares of common stock directly, and 36,152 RSUs and 36,150 Non-Qualified Stock Options indirectly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting ongoing executive compensation and alignment of interests through new equity grants, balanced by routine tax-related share dispositions.

Positives

• The Chief Operations Officer received a significant grant of 36,152 Restricted Stock Units and 36,150 Non-Qualified Stock Options, indicating continued long-term incentive compensation.
• The vesting of previously granted restricted stock units resulted in the acquisition of 4,617 common shares, increasing direct ownership.

Negatives

• A total of 1,627 shares of common stock were disposed of at $27.17 per share to cover tax withholding obligations, representing a reduction in direct share ownership.

Future Outlook

The filing details future vesting schedules for newly granted Restricted Stock Units and Non-Qualified Stock Options, indicating that 12,050 RSU shares and one-third of 36,150 stock option shares will vest on January 30, 2027, with further installments in 2028 and 2029. The stock options have an expiration date of January 30, 2036.

Industry Context

StockSavvy.ai notes that the grant of restricted stock units and non-qualified stock options to a Chief Operations Officer is a standard practice in the life sciences and diagnostics industry for executive compensation, aligning management incentives with long-term shareholder value. The vesting schedules are typical for retaining key executives over several years.

Comparison to Industry Standards

• The structure of equity compensation, including RSUs and stock options with multi-year vesting schedules, is consistent with common practices observed in comparable companies within the medical technology and diagnostics sector, such as Danaher Corporation, Abbott Laboratories, and Thermo Fisher Scientific, which frequently use similar long-term incentive plans to attract and retain executive talent.
• The disposition of shares for tax withholding purposes upon RSU vesting is a standard and expected event, reflecting the tax treatment of equity compensation.

Related Party Transactions

• The transactions involve the grant and vesting of equity compensation from QuidelOrtho Corp to its Chief Operations Officer, Philip D. McLellan, which are standard related-party dealings in the context of executive compensation.

Stakeholder Impact

• Shareholders: The grant of new equity compensation to a key executive aligns management's interests with long-term shareholder value. The tax-related dispositions are routine and have minimal impact.
• Employees: The compensation structure reflects the company's approach to executive incentives, which can influence broader employee compensation strategies.

Next Steps

• 12,050 shares of newly acquired Restricted Stock Units will vest on January 30, 2027.
• One-third of the 36,150 newly acquired Non-Qualified Stock Options will vest on January 30, 2027.
• Remaining newly acquired Restricted Stock Units (24,102 shares) will vest in equal installments on January 30, 2028, and January 30, 2029.
• Remaining newly acquired Non-Qualified Stock Options will vest in equal installments on January 30, 2028, and January 30, 2029.
• The newly acquired Non-Qualified Stock Options will expire on January 30, 2036.

Key Dates

Recommendation

The filing details routine executive compensation activities, including new equity grants and the vesting of prior awards with associated tax withholdings. These transactions are expected and do not indicate a significant change in the company's fundamental outlook or a strong directional signal for the stock, thus warranting a 'hold' recommendation.

Keywords

QuidelOrtho Corp, QDEL, Philip D. McLellan, Chief Operations Officer, SEC Form 4, Insider Trading, Restricted Stock Units, Stock Options, Equity Compensation, Tax Withholding, Beneficial Ownership